Kawasaki disease for the paediatric dermatologist: skin manifestations and new insights into the pathophysiology.
BCG Vaccine
/ adverse effects
Child
Diagnosis, Differential
Early Diagnosis
Edema
/ etiology
Erythema
/ etiology
Exanthema
/ etiology
Foot
/ pathology
Hand
/ pathology
Humans
Ischemia
/ etiology
Lip
/ pathology
Mucocutaneous Lymph Node Syndrome
/ diagnosis
Nails, Malformed
/ pathology
Skin
/ pathology
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
08
12
2020
received:
23
05
2020
accepted:
12
01
2021
pubmed:
17
1
2021
medline:
30
10
2021
entrez:
16
1
2021
Statut:
ppublish
Résumé
Early diagnosis of Kawasaki disease (KD) is critical to allow prompt initiation of treatment and avoid cardiac complications. All children with KD have fever accompanied by clinical signs, with four of the five classic criteria for complete KD being mucocutaneous, thus creating an important role for dermatologists. Moreover, dermatologists must be familiar with other dermatological findings that are not included in the American Heart Association classification criteria but can support the diagnosis, particularly in incomplete forms of the disease. We review the skin manifestations described for KD and perform an overview of pathophysiological advances and new treatments.
Substances chimiques
BCG Vaccine
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
503-509Informations de copyright
© 2021 British Association of Dermatologists.
Références
McCrindle BW, Rowley AH, Newburger JW et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017; 135: e927-99.
Bayers S, Shulman ST, Paller AS. Kawasaki disease: part I. Diagnosis, clinical features, and pathogenesis. J Am Acad Dermatol 2013; 69: 501.e1-11; quiz 511-12.
Piram M, Darce Bello M, Tellier S et al. Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease. Sci Rep 2020; 10: 3125.
Okada S, Hirano R, Okazaki-Emi S et al. Erythema multiforme- and not erythema multiforme-like rashes in Kawasaki disease. Pediatr Int 2019; 61: 1272-4.
Kamath S, Gurnee EA, Schenck OL et al. Pustular eruption in Kawasaki disease. J Pediatr 2019; 213: 241-e1.
Haddock ES, Calame A, Shimizu C et al. Psoriasiform eruptions during Kawasaki disease (KD): a distinct phenotype. J Am Acad Dermatol 2016; 75: 69-76.e2.
Demir F, Abul MH, Dilber E et al. A case of Kawasaki disease presenting with atypical cutaneous involvement and mimicking Stevens-Johnson syndrome. North Clin Istanb 2020; 7: 67-70.
Sato N, Sagawa K, Sasaguri Y et al. Immunopathology and cytokine detection in the skin lesions of patients with Kawasaki disease. J Pediatr 1993; 122: 198-203.
Eberhard BA, Sundel RP, Newburger JW et al. Psoriatic eruption in Kawasaki disease. J Pediatr 2000; 137: 578-80.
Vignesh P, Singh S. Perianal skin peeling: an important clinical pointer toward Kawasaki disease. Eur J Rheumatol 2018; 5: 81-2.
Wang S, Best BM, Burns JC. Periungual desquamation in patients with Kawasaki disease. Pediatr Infect Dis J 2009; 28: 538-9.
Garrido-Garcia LM, Castillo-Moguel A, Vazquez-Rivera M et al. Reaction of the BCG scar in the acute phase of Kawasaki disease in Mexican children. Pediatr Infect Dis J 2017; 36: e237-41.
Araki T, Kodera A, Kitada K et al. Analysis of factors associated with development of Bacille Calmette-Guérin inoculation site change in patients with Kawasaki disease. J Int Med Res 2018; 46: 1640-8.
Pal P, Giri PP. Orange-brown chromonychia, a novel finding in Kawasaki disease. Rheumatol Int 2013; 33: 1207-9.
Thapa R, Pal P. Transverse orange-brown chromonychia in Kawasaki disease. Int J Dermatol 2010; 49: 227-8.
Yamazaki-Nakashimada MA, Deguchi K, Gamez-Gonzalez B et al. Orange-brown chromonychia: a valid sign in Kawasaki disease in children of different ethnicities. Int J Rheum Dis 2019; 22: 1160-1.
Tessarotto L, Rubin G, Bonadies L et al. Orange-brown chromonychia and Kawasaki disease: a possible novel association? Pediatr Dermatol 2015; 32: e104-5.
Jindal AK, Bishnoi A, Dogra S, Singh S. A unique combination of nail changes in a boy with Kawasaki disease. J Clin Rheumatol 2020; 26: e210-11.
Berard R, Scuccimarri R, Chedeville G. Leukonychia striata in Kawasaki disease. J Pediatr 2008; 152: 889.
Mohsin M, Akhtar S. Kawasaki disease complicated by peripheral gangrene and a ventricular septal defect: an unusual association. Turk J Pediatr 2019; 61: 301-4.
Malekzadeh I, Ziaee V, Sadrosadat T et al. Kawasaki disease and peripheral gangrene in infancy. Iran J Pediatr 2015; 25: e3309.
Durall AL, Phillips JR, Weisse ME, Mullett CJ. Infantile Kawasaki disease and peripheral gangrene. J Pediatr 2006; 149: 131-3.
Paller AS, Mancini AJ. Disorders of hair and nails. Hurwitz's pediatric dermatology. Chapter 7, 4th edn, Edinburgh: Elsevier Saunders; 2011; 159.
Leung AKC, Leong KF, Lam JM. Onychomadesis in a 20-month-old child with Kawasaki disease. Case Rep Pediatr 2019; 2019: 3156736.
Kim GB. Reality of Kawasaki disease epidemiology. Korean J Pediatr 2019; 62: 292-6.
Tirelli F, Marrani E, Giani T, Cimaz R. One year in review: Kawasaki disease. Curr Opin Rheumatol 2020; 32: 15-20.
Piram M, Maldini C, Mahr A. Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. Curr Opin Rheumatol 2012; 24: 193-200.
Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat Rev Rheumatol 2020; 16: 391-405.
Burgner D, Harnden A. Kawasaki disease: what is the epidemiology telling us about the etiology? Int J Infect Dis 2005; 9: 185-94.
Burns JC, Kone-Paut I, Kuijpers T et al. Review: found in translation: international initiatives pursuing interleukin-1 blockade for treatment of acute Kawasaki disease. Arthritis Rheumatol 2017; 69: 268-76.
Hoang LT, Shimizu C, Ling L et al. Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease. Genome Med 2014; 6: 541.
Alphonse MP, Duong TT, Shumitzu C et al. Inositol-triphosphate 3-kinase C mediates inflammasome activation and treatment response in Kawasaki disease. J Immunol 2016; 197: 3481-9.
Kone-Paut I, Cimaz R, Herberg J et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun Rev 2018; 17: 768-74.
Zheng X, Yue P, Liu L et al. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: current evidence based on a meta-analysis. PLoS One 2019; 14: e0217274.